People · Operator
Named in public records as an officer, director or promoter · active 2018–2025 · Biotechnology, Biotech, Other Technology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vineti, Inc. | — | Biotechnology | Series C | $115.7M | $2.8B | 2018 |
| Octave Bioscience Inc | — | Biotech | Series B | $105.8M | $169.3M | 2020 |
| Alpha Source, Inc. | — | Other Technology | Series C | $102.7M | $154.7M | 2022 |
| TwinStrand Biosciences, Inc. | — | Biotech / Pharma | Series C | $85.0M | $132.2M | 2021 |
Michael Pellini at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Pellini on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mike Pellini | 2 | 3 |
| Brook Byers | 1 | 13 |
| Chad Waite | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Emily Melton | 1 | 10 |
| Risa Stack | 1 | 9 |
| Rowan Chapman | 1 | 7 |
| Steve Dow | 1 | 7 |
| Andrea Jackson | 1 | 6 |
| Thomas Hawes | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Soma Somasegar | 1 | 5 |
| Jason Myers | 1 | 4 |
| ANDREW HARRISON | 1 | 4 |
| William Hagstrom | 1 | 4 |
| George Scangos | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Chris Krueger | 1 | 3 |
| Jesse Salk | 1 | 3 |
| Christopher Benoit | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.